contact@king-theme.com   +1 123-456-7890
    Early Assessment of Pharmaceutical Formulations using OptiPharma Kit: A case study on Proprietary Pharmaceutical Protein

    Early Assessment of Pharmaceutical Formulations using OptiPharma Kit: A case study on Proprietary Pharmaceutical Protein

    Keywords: Protein Solubilization, Pharmaceutical Formulation, Formulation Development, Protein Aggregation, Protein Physical Stability Our previous blog describes the use of OptiPharma kit on α-chymotrypsin, commercially available protein. Here we are presenting a formulation study on a proprietary pharmaceutical protein (protein X, molecular weight of 70 kDa) using the OptiPharma Kit III. Figure 1 shows an overview of experimental procedure using an OptiPharma kit. In this experiment, read more...

    Identifying Pharmaceutical Excipients and Solution Conditions for α-Chymotrypsin using OptiPharma Kit

    Identifying Pharmaceutical Excipients and Solution Conditions for α-Chymotrypsin using OptiPharma Kit

    Formulation development is one of the critical steps in developing a protein as a therapeutic product. Maintaining the integrity of purified protein during pharmaceutical processing, storage, handling, and delivery to patient is a major challenge. There are many solution conditions (e.g. buffer pH, ionic charge, concentration, etc.) and pharmaceutical excipients which one can choose and combine to achieve the best condition for a solubilized protein. read more...

    High-Throughput Method to Formulate and Solubilize Proteins using SolubleBioScience Optisol Kit

    High-Throughput Method to Formulate and Solubilize Proteins using SolubleBioScience Optisol Kit

    A major hurdle for biologics development is the determination of a formulation that keeps a protein soluble. SolubleBioScience OptiSol Protein Solubilization Screening Kit (96-well format) contains a systematically varied array of buffers (from pH 3 to pH 10) and a series of solubility enhancers (salts, amino acids, sugars, polyols, reducing agents). Parallel filtration of the protein through multimer-excluding MWCO filters enables rapid identification of solubilizing read more...

    New biotech company giving private-sector boost to SA drug development research

    New biotech company giving private-sector boost to SA drug development research

    SolubleBioScience has yet to move its headquarters to San Antonio, but it's already having a direct impact on advancing drug development in the Alamo City. The Birmingham, Alabama-based biotech company, recently acquired by CytoBioscience, is contributing new technology to the Center for Innovative Drug Discovery that could prove to be a game changer for researchers and patients. SolubleBioScience, a new wholly owned subsidiary of CytoBioscience, read more...

    Former German firm bringing more biotech business to San Antonio

    Former German firm bringing more biotech business to San Antonio

    San Antonio’s successful recruitment of Cytocentrics more than a year ago has led to another economic win that could further enhance the city’s role in the global bioscience arena. The company, which recently changed its name to CytoBioScience Inc., has acquired a Birmingham, Alabama-based biotech firm called Soluble Therapeutics that will look to establish roots here over the next 12 months. CytoBioScience officials believe the read more...

    Soluble Therapeutics Acquired by CytoBioscience

    Soluble Therapeutics Acquired by CytoBioscience

    SAN ANTONIO--(BUSINESS WIRE)--CytoBioscience, Inc. has purchased Birmingham, Alabama-based Soluble Therapeutics and will move the company’s operations to its San Antonio location. The deal closed November 1, according to James Garvin, Chief Executive Officer of CytoBioscience. Details of the multi-million dollar purchase price were not disclosed. “The Soluble Therapeutics team has created a business offering that aligns very well with our technology and work to positively read more...